Kim Blickenstaff compensation by year
TANDEM DIABETES CARE Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $569,006 | $583,495 | $1 | $500,000 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 |
| Option awards | $866,656 | $160,338 | $2,395,065 | $9,243,268 |
| Non-equity incentive | $0 | $0 | $583,495 | $796,792 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $2,772 | $5,334 | $4,924 | $4,897 |
| Total | $1,438,434 | $749,167 | $2,983,485 | $10,544,957 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TANDEM DIABETES CARE INC DEF 14A filed April 15, 2020, accession 0001438133-20-000032, and prior-year filings.
How this page was built: the TANDEM DIABETES CARE INC filed document, accession 0001438133-20-000032. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 50,000 | — | $18.86 |
| Option | 11,152 | — | $9.00 |
| Option | 986 | — | $69.50 |
| Option | 210,000 | — | $51.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in TANDEM DIABETES CARE INC's FY2019 proxy; value at the fiscal year-end close, as the company printed it.
TANDEM DIABETES CARE’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| John Sheridan | President and Chief Executive Officer | $10,560,937 |
| Kim Blickenstaff · this page | Current Chairman of the Board of Directors Former Executive Chairman of the Board of Directors, and Former President and Chief Executive Officer | $10,544,957 |
| Brian Hansen | Executive Vice President, Chief Commercial Officer | $5,399,897 |
| Leigh Vosseller | Executive Vice President, Chief Financial Officer and Treasurer | $5,391,452 |
| David Berger | Executive Vice President, Chief Legal and Compliance Officer & Corporate Secretary (5) | $5,390,888 |
| Susan Morrison | Executive Vice President, Chief Administrative Officer | $5,390,241 |
Board service
TANDEM DIABETES CARE board · FY2021–FY2023| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $73,833 | $124,950 | — | — | $198,783 |
| FY2022 | $130,083 | $179,977 | — | — | $310,060 |
| FY2021 | $164,667 | $179,994 | — | — | $344,661 |
Each year as the company reported it in TANDEM DIABETES CARE's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: TANDEM DIABETES CARE pays directors a $60,000 cash retainer and $180,000 in equity. As stated in TANDEM DIABETES CARE's FY2025 proxy.
The full TANDEM DIABETES CARE compensation record
free company briefThis page is one person within TANDEM DIABETES CARE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the TANDEM DIABETES CARE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TANDEM DIABETES CARE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.